Intervention Protocol

Olanzapine depot for schizophrenia

  1. Isuru Herath Mudiyanselage2,
  2. Jagannathan Alagarsamy1,*,
  3. Sandhya Kachhap3,
  4. Mahesh B Jayaram4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 8 JUL 2009

Assessed as up-to-date: 29 MAR 2009

DOI: 10.1002/14651858.CD007947

How to Cite

Herath Mudiyanselage I, Alagarsamy J, Kachhap S, Jayaram MB. Olanzapine depot for schizophrenia (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007947. DOI: 10.1002/14651858.CD007947.

Author Information

  1. 1

    Logan Hospital, Brisbane, Queensland, Australia

  2. 2

    Leeds Partnership Foundation Trust, General Adult Psychiatry, Crisis Resolution Team, Leeds, UK

  3. 3

    Redlands Hospital, Cleveland, Queensland, Australia

  4. 4

    Leeds Partnership Foundation NHS Trust, CMHT, Leeds, UK

*Jagannathan Alagarsamy, Logan Hospital, Cnr Loganlea and Armstrong Roads, Meadowbrook 4131, Brisbane, Queensland, Australia.

Publication History

  1. Publication Status: New
  2. Published Online: 8 JUL 2009




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the effectiveness of olanzapine LAI (long-acting Injection) in comparison with placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia and other severe mental illnesses.